The Latest Breaking News from HRMY

The biotech industry's future appears bright due to advancements in biochemical and pharma technologies, AI integration, rising targeted treatments, and increased R&D spending driving breakthroughs. Therefore, it could be wise to invest in undervalued biotech stocks such as Harmony Biosciences Holdings (HRMY), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). Read…

Given growing healthcare spending, supportive government policies, and technological innovation, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider buying quality biotech stocks Harmony Biosciences (HRMY), Esperion Therapeutics (ESPR), and Entrada Therapeutics (TRDA), which are trading at a discount. Read on….

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

The biotech industry’s expansion stems from advancements in cutting-edge medical technologies and the growing demand for food biotechnology. Against this backdrop, should you buy Harmony Biosciences Holdings (HRMY), Exelixis (EXEL), and Surrozen (SRZN)? Let’s find out.

The biotech industry's expansion seems to stem from advancements in drug development, cutting-edge technology, and substantial government backing. Given these factors, prominent biotech stocks Surrozen (SRZN), Harmony Biosciences (HRMY), and Cidara Therapeutics (CDTX) could be solid watchlist additions now. Read on….

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

Harmony Biosciences beat EPS and sales expectations last quarter, sending shares up over 12%.

Biotech stock United Therapeutics joins peers Vertex and Harmony Biosciences on the Breakout Stocks Index as it reenters a buy zone.

Pulled from Benzinga Pro data, Harmony Biosciences (NASDAQ:HRMY) posted Q1 earnings of $21.48 million, an increase from Q4 of 5.41%. Sales dropped to $85.31 million, a 6.47% decrease between quarters.